366 related articles for article (PubMed ID: 7686448)
1. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
2. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
Bonardi MA; Bell A; French RR; Gromo G; Hamblin T; Modena D; Tutt AL; Glennie MJ
Int J Cancer Suppl; 1992; 7():73-7. PubMed ID: 1428411
[TBL] [Abstract][Full Text] [Related]
3. Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.
French RR; Courtenay AE; Ingamells S; Stevenson GT; Glennie MJ
Cancer Res; 1991 May; 51(9):2353-61. PubMed ID: 2015599
[TBL] [Abstract][Full Text] [Related]
4. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
6. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
7. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
Glennie MJ; Brennand DM; Bryden F; McBride HM; Stirpe F; Worth AT; Stevenson GT
J Immunol; 1988 Nov; 141(10):3662-70. PubMed ID: 3141503
[TBL] [Abstract][Full Text] [Related]
8. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
9. Response of B-cell lymphoma to a combination of bispecific antibodies and saporin.
French RR; Bell AJ; Hamblin TJ; Tutt AL; Glennie MJ
Leuk Res; 1996 Jul; 20(7):607-17. PubMed ID: 8795695
[TBL] [Abstract][Full Text] [Related]
10. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
11. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
[TBL] [Abstract][Full Text] [Related]
14. Membrane CD22 defines circulating myeloma-related cells as mature or later B cells.
Perfetti V; Vignarelli MC; Bellotti V; Glennie MJ; Zorzoli I; Ubbiali P; Obici L; Massa M; Ippoliti G; Ascari E; Merlini G
Lab Invest; 1997 Oct; 77(4):333-44. PubMed ID: 9354768
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
Flavell DJ; Cooper S; Morland B; Flavell SU
Br J Cancer; 1991 Aug; 64(2):274-80. PubMed ID: 1716453
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules.
Flavell DJ; Cooper S; Morland B; French R; Flavell SU
Br J Cancer; 1992 Apr; 65(4):545-51. PubMed ID: 1373293
[TBL] [Abstract][Full Text] [Related]
17. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
18. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Shen GL; Li JL; Vitetta ES
J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
[TBL] [Abstract][Full Text] [Related]
19. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
20. B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking.
Chaouchi N; Vazquez A; Galanaud P; Leprince C
J Immunol; 1995 Apr; 154(7):3096-104. PubMed ID: 7534787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]